AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36568444 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 45
Study 36568559 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-albuminuric CKD with eGFR <45 mL/min/1.73 m²
Number of subjects: 8866
Study 36568559 — intervention group
Group type: COMPARATOR
Intervention: Non-albuminuric CKD with eGFR ≥60 mL/min/1.73 m²
Number of subjects: 8866
Study 36568789 — intervention group
Group type: EXPERIMENTAL
Intervention: WISER intervention (Web-based Implementation for the Science of Enhancing Resilience), delivered daily for 10 days.
Number of subjects: 482
Study 36568789 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (Cohort 2) before receiving WISER.
Number of subjects: 482
Study 36569122 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pregnant women of child-bearing age
Number of subjects: 799
Study 36569123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 37
Study 36569123 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine/glycopyrrolate
Number of subjects: 37
Study 36569131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Picosulphate plus Magnesium Citrate (SPMC)
Number of subjects: 550
Study 36569131 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene Glycol plus Ascorbic Acid (PEG-ASC)
Number of subjects: 550
Study 36569610 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course (SC) antidepressant therapy
Number of subjects: 0
Study 36569610 — intervention group
Group type: COMPARATOR
Intervention: Long-course (LC) antidepressant therapy
Number of subjects: 0
Study 36569610 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week FM therapy
Number of subjects: 0
Study 36569610 — intervention group
Group type: COMPARATOR
Intervention: 4-week FM therapy
Number of subjects: 0
Study 36569851 — intervention group
Group type: COMPARATOR
Intervention: Synbiotic (probiotic + prebiotic)
Number of subjects: 71
Study 36569851 — intervention group
Group type: COMPARATOR
Intervention: Probiotic
Number of subjects: 71
Study 36569851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 36569851 — intervention group
Group type: COMPARATOR
Intervention: Synbiotic
Number of subjects: 71
Study 36569881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab 200mg plus autologous NK cells
Number of subjects: 0
Study 36569905 — intervention group
Group type: EXPERIMENTAL
Intervention: AK104 (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy (mXELOX)
Number of subjects: 1
Study 36569905 — intervention group
Group type: EXPERIMENTAL
Intervention: AK104 (PD-1/CTLA-4 bispecific antibody) combined with single-drug capecitabine therapy
Number of subjects: 1
Study 36569905 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy combined with mycophenolate mofetil
Number of subjects: 1
Study 36569905 — intervention group
Group type: EXPERIMENTAL
Intervention: AK104 rechallenged after hormone therapy
Number of subjects: 1
Study 36569905 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1
Study 36569946 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71+IIV3
Number of subjects: 1045
Study 36569946 — intervention group
Group type: COMPARATOR
Intervention: EV71
Number of subjects: 1045
Study 36569946 — intervention group
Group type: COMPARATOR
Intervention: IIV3
Number of subjects: 1045
Study 36569951 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical transplantation with CD34-enriched cells and peripheral blood mononuclear cell addback
Number of subjects: 11
Study 36570150 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with probiotics (10 unspecified dosage)
Number of subjects: 50
Study 36570150 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet without probiotics (control group)
Number of subjects: 50
Study 36570150 — intervention group
Group type: EXPERIMENTAL
Intervention: Other unspecified dietary interventions
Number of subjects: 50
Study 36570171 — intervention group
Group type: EXPERIMENTAL
Intervention: Enema containing ReFerm
Number of subjects: 30
Study 36570498 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) 3 times a week + Treatment as Usual (TAU)
Number of subjects: 0
Study 36570498 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 0
Study 36570649 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily for 3 months
Number of subjects: 50
Study 36570649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 36570810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.5 mg/kg)
Number of subjects: 66
Study 36570810 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 66
Study 36570815 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy for divalent metals (lead and cadmium)
Number of subjects: 0
Study 36570815 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy
Number of subjects: 0
Study 36570815 — intervention group
Group type: COMPARATOR
Intervention: Legislation, mitigation and control of pollutants
Number of subjects: 0
Study 36570815 — intervention group
Group type: COMPARATOR
Intervention: Environmental policies for heart-healthy spaces
Number of subjects: 0
Study 36570829 — intervention group
Group type: EXPERIMENTAL
Intervention: Floatation-REST
Number of subjects: 57
Study 36570829 — intervention group
Group type: COMPARATOR
Intervention: Exteroceptive comparison condition (watching a relaxing nature film)
Number of subjects: 57
Study 36571164 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) for patients with underlying ICAD
Number of subjects: 315
Study 36571164 — intervention group
Group type: COMPARATOR
Intervention: Endovascular therapy (EVT) for patients without underlying ICAD
Number of subjects: 315
Study 36571171 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chlorpheniramine 10 mg and ranitidine 50 mg
Number of subjects: 40
Study 36571171 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 40
Study 36571569 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor/aspirin
Number of subjects: 5796
Study 36571569 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel/aspirin
Number of subjects: 5796
Study 36571611 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cetirizine with minoxidil
Number of subjects: 66
Study 36571611 — intervention group
Group type: COMPARATOR
Intervention: Topical minoxidil with placebo
Number of subjects: 66
Study 36571701 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg once daily (QD) for induction
Number of subjects: 1683
Study 36571701 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg QD for maintenance
Number of subjects: 1683
Study 36571701 — intervention group
Group type: COMPARATOR
Intervention: Upadacitinib 15 mg QD for maintenance
Number of subjects: 1683
Study 36571701 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (various doses 7.5-45 mg QD for induction and 15-30 mg QD for maintenance)
Number of subjects: 1683
Study 36571701 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 1683
Study 36571770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg intravenously every 2 weeks until confirmed progression, unacceptable toxicity, or trial withdrawal.
Number of subjects: 83
Study 36571770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg intravenously every 2 weeks
Number of subjects: 83
Study 36571770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Number of subjects: 83
Study 36571826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy applied 10 minutes before port needle removal
Number of subjects: 0
Study 36571826 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 36571973 — intervention group
Group type: EXPERIMENTAL
Intervention: STIGMA video
Number of subjects: 49
Study 36571973 — intervention group
Group type: COMPARATOR
Intervention: NEUTRAL video
Number of subjects: 49
Study 36572129 — intervention group
Group type: EXPERIMENTAL
Intervention: Underwater EMR (UEMR)
Number of subjects: 298
Study 36572129 — intervention group
Group type: COMPARATOR
Intervention: Conventional EMR (CEMR)
Number of subjects: 298
Study 36572184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (P2B: pooled 200/300 mg; VENTURE: 300 mg) every 2 weeks
Number of subjects: 0
Study 36572184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36572202 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm rowing (AO)
Number of subjects: 27
Study 36572202 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) rowing
Number of subjects: 27
Study 36572202 — intervention group
Group type: COMPARATOR
Intervention: Control (no structured exercise)
Number of subjects: 27
Study 36572239 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Whole Health (18 sessions over 6 months)
Number of subjects: 220
Study 36572239 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC; primary care and data analytics)
Number of subjects: 220
Study 36572280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified neoadjuvant CRT followed by adjuvant CT
Number of subjects: 913
Study 36572280 — intervention group
Group type: COMPARATOR
Intervention: Total neoadjuvant therapy (TNT)
Number of subjects: 913
Study 36572373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 80
Study 36572373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 36572500 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided I-BA
Number of subjects: 32
Study 36572500 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided I-BA
Number of subjects: 32
Study 36572500 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 32
Study 36572501 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chest CT scan
Number of subjects: 500
Study 36572534 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine during pulmonary rehabilitation
Number of subjects: 71
Study 36572534 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain imaging markers of breathlessness-expectation
Number of subjects: 71
Study 36572534 — intervention group
Group type: COMPARATOR
Intervention: Questionnaires and clinical measures
Number of subjects: 71
Study 36572571 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib 400 mg (orally, twice daily, with an intermittent schedule of 4 days on, 3 days off) plus abiraterone acetate 1000 mg (orally administered once daily) and prednisone 5 mg (twice daily)
Number of subjects: 27
Study 36572869 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing clinics (15% of participants)
Number of subjects: 675
Study 36572869 — intervention group
Group type: COMPARATOR
Intervention: Not changing clinics (85% of participants)
Number of subjects: 675
Study 36572870 — intervention group
Group type: COMPARATOR
Intervention: Standard care well-child visits (WCV)
Number of subjects: 2025
Study 36572870 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome (PRO) measure (PRO WCV)
Number of subjects: 2025
Study 36572870 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO WCV plus Food Care (telehealth coaching and grocery store tour)
Number of subjects: 2025
Study 36572870 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (Standard WCV, PRO WCV, PRO WCV plus Food Care)
Number of subjects: 2025
Study 36572884 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week specific rehabilitation program combining education and exercises
Number of subjects: 66
Study 36572884 — intervention group
Group type: COMPARATOR
Intervention: Standardized education (Control)
Number of subjects: 66
Study 36573005 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID+ group
Number of subjects: 1000
Study 36573005 — intervention group
Group type: COMPARATOR
Intervention: COVID- group
Number of subjects: 1000
Study 36573071 — intervention group
Group type: EXPERIMENTAL
Intervention: Smiling is Fun (internet-based treatment)
Number of subjects: 420
Study 36573071 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control phase)
Number of subjects: 420
Study 36573318 — intervention group
Group type: EXPERIMENTAL
Intervention: MASES enthesitis score
Number of subjects: 526
Study 36573634 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron variant period
Number of subjects: 0
Study 36573634 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta variant period
Number of subjects: 0
Study 36573634 — intervention group
Group type: COMPARATOR
Intervention: Pre-Delta variant period
Number of subjects: 0
Study 36573634 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta and Omicron (pre-BA.4/BA.5) variant periods
Number of subjects: 0
Study 36573644 — intervention group
Group type: EXPERIMENTAL
Intervention: MAOA DNA methylation assessment via [11C]harmine PET
Number of subjects: 52
Study 36573651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (racemic ketamine hydrochloride) administered over a 40-minute intravenous infusion, 2 times per week on nonconsecutive days for 4 weeks (8 sessions)
Number of subjects: 30
Study 36573717 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride treatment
Number of subjects: 509
Study 36573717 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glimepiride (2-4 mg/day)
Number of subjects: 509
Study 36573804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of wholegrains, fiber, and resistant starch
Number of subjects: 0
Study 36573804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary quality in children with CF
Number of subjects: 0
Study 36573804 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal and respiratory microbiota analysis
Number of subjects: 0
Study 36574052 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC)
Number of subjects: 98
Study 36574052 — intervention group
Group type: COMPARATOR
Intervention: Usual oncology care (standard group, S)
Number of subjects: 98
Study 36574199 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi SoloStar pen
Number of subjects: 0
Study 36574199 — intervention group
Group type: EXPERIMENTAL
Intervention: Training by HCPs on iGlarLixi SoloStar pen
Number of subjects: 0
Study 36574199 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi SoloStar pen recommendation
Number of subjects: 0
Study 36574248 — intervention group
Group type: EXPERIMENTAL
Intervention: High-climate impact label (red meat)
Number of subjects: 5049
Study 36574248 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-climate impact label (chicken, fish, vegetarian)
Number of subjects: 5049
Study 36574248 — intervention group
Group type: COMPARATOR
Intervention: Control label (quick response code)
Number of subjects: 5049
Study 36574248 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-impact label
Number of subjects: 5049
Study 36574248 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact label
Number of subjects: 5049
Study 36574248 — intervention group
Group type: EXPERIMENTAL
Intervention: High-climate impact label
Number of subjects: 5049
Study 36574248 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-climate impact label
Number of subjects: 5049
Study 36574256 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-pronged COVID-19 vaccine messaging platform (4-minute video, 1-page flyer, scripted message from ED staff)
Number of subjects: 496
Study 36574256 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-pronged COVID-19 vaccine messaging platform
Number of subjects: 496
Study 36574256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no messaging platform)
Number of subjects: 496
Study 36574387 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG/EE TDS (delivering LNG 120 μg/day and EE 30 μg/day) for 12 weeks
Number of subjects: 36
Study 36574408 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Attachment-Based Compassion Therapy (iABCT)
Number of subjects: 68
Study 36574408 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 68
Study 36574413 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telemonitoring program
Number of subjects: 0
Study 36574413 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 36574434 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid glucose infusion (3 times 20 grams of glucose i.v. over 5 minutes)
Number of subjects: 10
Study 36574434 — intervention group
Group type: COMPARATOR
Intervention: Continuous glucose infusion (60 grams of glucose continuously over 3 hours)
Number of subjects: 10
Study 36574590 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg daily
Number of subjects: 28
Study 36574590 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 28
Study 36574595 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ruxolitinib cream
Number of subjects: 1072
Study 36574595 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream
Number of subjects: 1072
Study 36574595 — intervention group
Group type: COMPARATOR
Intervention: vehicle to 0.75% ruxolitinib cream
Number of subjects: 1072
Study 36574595 — intervention group
Group type: COMPARATOR
Intervention: vehicle to 1.5% ruxolitinib cream
Number of subjects: 1072
Study 36574595 — intervention group
Group type: EXPERIMENTAL
Intervention: ruxolitinib cream (both strengths)
Number of subjects: 1072
Study 36574616 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training (MT) physical exercise intervention
Number of subjects: 36
Study 36574616 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 36574734 — intervention group
Group type: EXPERIMENTAL
Intervention: self-monitoring of diet, PA, and weight with tailored feedback messages (n = 251)
Number of subjects: 502
Study 36574734 — intervention group
Group type: COMPARATOR
Intervention: self-monitoring alone (n = 251)
Number of subjects: 502
Study 36574828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg)
Number of subjects: 60
Study 36574828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambezim-G (trypsin 5mg-chymotrypsin 5 mg)
Number of subjects: 60
Study 36574828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen and trypsin-chymotrypsin
Number of subjects: 60
Study 36574828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 36574867 — intervention group
Group type: EXPERIMENTAL
Intervention: BiVP with optimal AV delays derived from shortest VS1 and longest S1S2 in pigs
Number of subjects: 26
Study 36574867 — intervention group
Group type: EXPERIMENTAL
Intervention: BiVP with optimal AV delays derived from shortest VS1 and longest S1S2 in patients
Number of subjects: 26
Study 36574867 — intervention group
Group type: EXPERIMENTAL
Intervention: BiVP with full-capture AV delay of >180 ms in patients
Number of subjects: 26
Study 36574985 — intervention group
Group type: EXPERIMENTAL
Intervention: Community perceptions about COVID-19
Number of subjects: 10
Study 36574985 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma associated with COVID-19
Number of subjects: 10
Study 36574985 — intervention group
Group type: EXPERIMENTAL
Intervention: Community attitudes towards COVID-19
Number of subjects: 10
Study 36574985 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of stigma on mental health
Number of subjects: 10
Study 36575175 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry powder inhalers (DPIs)
Number of subjects: 1400
Study 36575175 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation technique observation
Number of subjects: 1400
Study 36575175 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence assessment
Number of subjects: 1400
Study 36575175 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person observation of inhalation technique
Number of subjects: 1400
Study 36575175 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation training for healthcare professionals
Number of subjects: 1400
Study 36575298 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube biofilm (ETT-BF)
Number of subjects: 61
Study 36575315 — intervention group
Group type: EXPERIMENTAL
Intervention: Wave 1 (first COVID wave)
Number of subjects: 772
Study 36575315 — intervention group
Group type: COMPARATOR
Intervention: Wave 2 (second COVID wave)
Number of subjects: 772
Study 36575361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus 8 Gy single fraction radiation therapy (RT)
Number of subjects: 28
Study 36575390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided SHPN using 3 ml 5% bupivacaine plus 20 ml 10% phenol
Number of subjects: 96
Study 36575390 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopic-guided SHPN using 3 ml 5% bupivacaine plus 20 ml 10% phenol
Number of subjects: 96
Study 36575394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior paracetamol intake
Number of subjects: 2646
Study 36575394 — intervention group
Group type: COMPARATOR
Intervention: No prior paracetamol intake
Number of subjects: 2646
Study 36575421 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting internal mammary node irradiation (IMNI)
Number of subjects: 214
Study 36575421 — intervention group
Group type: COMPARATOR
Intervention: With internal mammary node irradiation (IMNI)
Number of subjects: 214
Study 36575425 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based therapy
Number of subjects: 0
Study 36575425 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled carbon dioxide (CO)
Number of subjects: 0
Study 36575444 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC (Cetylpyridinium Chloride)
Number of subjects: 0
Study 36575444 — intervention group
Group type: EXPERIMENTAL
Intervention: O-cymen-5-ol
Number of subjects: 0
Study 36575444 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC + O-cymen-5-ol
Number of subjects: 0
Study 36575505 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase + oral methotrexate (15 mg/week) administered 4 weeks before and during pegloticase treatment (biweekly 8 mg infusion, ≤ 52 weeks)
Number of subjects: 14
Study 36575505 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 14